Form 8-K - Current report:
SEC Accession No. 0001213900-24-036645
Filing Date
2024-04-26
Accepted
2024-04-26 16:13:53
Documents
15
Period of Report
2024-04-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0204751-8k_oncone.htm   iXBRL 8-K 33780
2 FORBEARANCE AGREEMENT, DATED APRIL 24, 2024, BETWEEN THE COMPANY AND VERU ea020475101ex10-1_oncone.htm EX-10.1 48885
3 AMENDMENT TO NON-CONVERTIBLE DEBENTURE, DATED APRIL 24, 2024, BETWEEN THE COMPAN ea020475101ex10-2_oncone.htm EX-10.2 13922
  Complete submission text file 0001213900-24-036645.txt   288721

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE onco-20240424.xsd EX-101.SCH 3042
5 XBRL LABEL FILE onco-20240424_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE onco-20240424_pre.xml EX-101.PRE 22377
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0204751-8k_oncone_htm.xml XML 3795
Mailing Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202
Business Address 201 E. FIFTH STREET SUITE 1900 CINCINNATI OH 45202 513-620-4101
Onconetix, Inc. (Filer) CIK: 0001782107 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41294 | Film No.: 24883911
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)